Sofosbuvir and ABT-450: Terminator of hepatitis C virus?

Table 3 Overview of 50 hepatitis C patients under ABT-450 regimen

Group	n	Genotype (n)	Status before treatment	Therapeutic schedule	Usage	SVR rate2
1	19	1a/1b (17/2)	Untreated	ABT-450 + ritonavir + ABT-333 + RBV 12 wk	ABT-450, 250 mg (qd)	95%
					Ritonavir, 100 mg (qd)
					ABT-333, 400 mg (bid)
					RBV, 1000 or 1200 mg/d1
2	14	1a/1b (11/3)	Untreated	ABT-450 + ritonavir + ABT-333 + RBV 12 wk	ABT-450, 150 mg (qd)	93%
					Ritonavir + ABT-333 + RBV Ditto
3	17	1a/1b (16/1)	No or partial response to prior therapy	ABT-450 + ritonavir + ABT-333 + RBV 12 wk	ABT-450, 150 mg (qd)	47%
					Ritonavir + ABT-333 + RBV Ditto

¹Body weight < 75 kg, 1000 mg/d, divided into doses of 400 and 600 mg, bid; Body weight ≥ 75 kg, 1200 mg/d, 600 mg, bid;

²Sustained virologic response (SVR) in this study was defined as an